Lenacapavir - Wikipedia
Lenacapavir, sold under the brand name Sunlenca, is an antiretroviral medication used to treat HIV/AIDS. [9][10] It is taken by mouth or by subcutaneous injection. [9][10] The most common side effects include reactions at the injection site and nausea. [10][11]
Lenacapavir oral/injection Uses, Side Effects & Warnings - Drugs.com
2023年2月14日 · What is lenacapavir? Lenacapavir is used in adults with other antiviral drugs to treat HIV, the virus that can cause acquired immunodeficiency syndrome (AIDS). Lenacapavir is not a cure for HIV or AIDS. Lenacapavir is given after several other HIV medications did not work, have stopped working or could not be tolerated.
Lenacapavir 300 Mg Tablet - Uses, Side Effects, and More - WebMD
Lenacapavir is used with other HIV medications to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers...
Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in …
2024年7月24日 · Lenacapavir is a novel, first-in-class, multistage HIV-1 capsid inhibitor with high potency and a long half-life, allowing administration by subcutaneous injection twice yearly. 10,11 Tenofovir...
Long-acting injectable lenacapavir continues to show promising …
2024年9月26日 · LEN, an HIV-1 capsid inhibitor delivered by subcutaneous injection twice a year, was shown to be highly effective in preventing HIV among cisgender men, transgender men, transgender women, and gender non-binary individuals …
Lenacapavir Patient Drug Record | NIH - Clinicalinfo
2024年1月7日 · Lenacapavir (brand name: Sunlenca) is a prescription medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of HIV infection in adults for whom other HIV medicines have not worked and who meet certain requirements, as determined by a health care provider.
Twice-yearly HIV injection can effectively prevent infection
2024年12月3日 · Lenacapavir, an antiretroviral drug typically used to treat HIV infections, can also effectively prevent them, a phase 3 clinical trial has shown.
Lenacapavir (HIV Prevention) Patient Drug Record | NIH
2024年11月19日 · Lenacapavir is a drug that has been approved by the U.S. Food and Drug Administration (FDA) under the brand name Sunlenca for the treatment of HIV. 4 Lenacapavir is also being studied as an investigational drug to prevent HIV infection. 2,3
Lenacapavir (oral route) - Mayo Clinic
It works by lowering the amount of HIV in the blood and helps the immune system. This may help delay some of the medical conditions that usually result from AIDS or HIV disease. It will not keep you from spreading HIV to other people. This medicine is …
Lenacapavir: A Novel Capsid Inhibitor in HIV-1 Treatment and …
2024年11月23日 · Lenacapavir’s unique, long-acting mechanism of action, targeting the viral capsid, demonstrates substantial antiviral efficacy with reduced dosing frequency and an impressive safety profile, making it a potential game-changer in managing HIV-1 infection.
- 当前正在显示可能无法访问的结果。隐藏无法访问的结果